Department of Pharmaceutics, Faculty of Pharmacy, DIT University, Dehradun, India.
Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
Biochim Biophys Acta Gen Subj. 2021 Feb;1865(2):129777. doi: 10.1016/j.bbagen.2020.129777. Epub 2020 Oct 29.
Background In past few decades, the research on engineered nanocarriers (NCs) has gained significant attention in cancer therapy due to selective delivery of drug molecules on the diseased cells thereby preventing unwanted uptake into healthy cells to cause toxicity. Scope of review The applicability of enhanced permeability and retention (EPR) effect for the delivery of nanomedicines in cancer therapy has gained limited success due to poor accessibility of the drugs to the target cells where non-specific payload delivery to the off target region lack substantial reward over the conventional therapeutic systems. Major conclusions In spite of the fact, nanomedicines fabricated from the biocompatible nanocarriers have reduced targeting potential for meaningful clinical benefits. However, over expression of receptors on the tumor cells provides opportunity to design functional nanomedicine to bind substantially and deliver therapeutics to the cells or tissues of interest by alleviating the bio-toxicity and unwanted effects. This critique will give insight into the over expressed receptor in various tumor and targeting potential of functional nanomedicine as new therapeutic avenues for effective treatment. General significance This review shortly shed light on EPR-based drug targeting using nanomedicinal strategies, their limitation, and advances in therapeutic targeting to the tumor cells.
背景 在过去的几十年中,由于工程纳米载体 (NCs) 能够将药物分子选择性递送到病变细胞,从而防止药物进入健康细胞引起毒性,因此在癌症治疗中对其的研究引起了广泛关注。
综述范围 增强型通透性和保留 (EPR) 效应在癌症治疗中递送纳米药物的适用性由于药物难以到达靶细胞而受到限制,因为非特异性有效载荷向非靶区域的输送并不能为传统治疗系统带来实质性的益处。
主要结论 尽管如此,由生物相容性纳米载体制成的纳米药物在具有意义的临床获益方面的靶向潜力降低了。然而,肿瘤细胞上过表达的受体为设计功能纳米药物提供了机会,通过减轻生物毒性和不良反应,这些功能纳米药物可以与细胞或组织结合并输送治疗药物。本综述将深入探讨各种肿瘤中过表达的受体以及功能纳米药物的靶向潜力,为有效的治疗提供新的治疗途径。
总体意义 本综述简要介绍了基于 EPR 的药物靶向纳米医学策略,以及它们的局限性和治疗靶向肿瘤细胞的进展。
Biochim Biophys Acta Gen Subj. 2021-2
J Control Release. 2016-11-18
AAPS PharmSciTech. 2020-5-14
Adv Drug Deliv Rev. 2017-3-7
Int J Nanomedicine. 2024
J Control Release. 2016-10-28
Eur J Pharm Biopharm. 2015-6
Acc Chem Res. 2019-5-23
Drug Des Devel Ther. 2024
Molecules. 2024-2-29
Discov Nano. 2024-3-7
Pharmaceuticals (Basel). 2023-2-24